Thus, these results suggested that a subpopulation of patients with EGFR mutations and NSCLC developed first generation EGFR-TKI resistance because of increased heregulin expression, but that such patients might retain afatinibsensitivity. This evidence concerns the gene EGFR and non-small cell lung carcinoma.